Healthcare Archives - Page 12 of 13 - Boston Life Sciences Times

Agenus Reports Durable Responses in Refractory Ovarian Cancer With Botensilimab and Balstilimab

December 23, 2025

Quanterix Nature Study Redefines Prevalence of Alzheimer’s Disease Neuropathology in General Population

December 22, 2025

Alnylam to Invest $250 Million to Expand U.S. Manufacturing With Enzymatic Ligation Platform

December 17, 2025

THIS WEEK'S STORIES

Vyome Subsidiary LiveChain Moves to Acquire Senior Secured Note in MIT-Backed Humanyze

December 22, 2025

Agenus Reports Durable Responses in Refractory Ovarian Cancer With Botensilimab and Balstilimab

December 23, 2025

Viridian Therapeutics Secures FDA Acceptance and Priority Review for Veligrotug in Thyroid Eye Disease

December 22, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Healthcare

Physician-Led Arches Massachusetts IPA Partners With Valley Medical Group to Expand Value-Based Care Model

Byron Jobe Named One of Modern Healthcare’s 100 Most Influential People in Healthcare

Podimetrics Releases Provider Insights Report to Help Prevent Diabetic Foot Ulcers and Reduce Amputations

Boston IVF Expands Financing Options Through Partnerships With Gaia and PatientFi

FDA Approves Cleveland Diagnostics’ IsoPSA Test for Improved Prostate Cancer Risk Assessment

Most Read

FDA Approves Edwards Lifesciences’ SAPIEN M3 as First Transseptal Transcatheter Mitral Valve Replacement

RevBio Receives FDA Clearance to Launch Dental Clinical Trial for Regenerative Bone Glue

Enveda Advances Third Drug Candidate Into Clinic With FDA Clearance for ENV-6946

Startup Shutdowns Shift to Later Stages as First AI Reckoning Emerges, Report Finds

EDITOR PICKS

Agenus Reports Durable Responses in Refractory Ovarian Cancer With Botensilimab and Balstilimab

Quanterix Nature Study Redefines Prevalence of Alzheimer’s Disease Neuropathology in General Population

Alnylam to Invest $250 Million to Expand U.S. Manufacturing With Enzymatic Ligation Platform

THIS WEEK'S STORIES

Vyome Subsidiary LiveChain Moves to Acquire Senior Secured Note in MIT-Backed Humanyze

Agenus Reports Durable Responses in Refractory Ovarian Cancer With Botensilimab and Balstilimab

Viridian Therapeutics Secures FDA Acceptance and Priority Review for Veligrotug in Thyroid Eye Disease

POPULAR CATEGORY

ABOUT US

FOLLOW US